Literature DB >> 9061094

Morphine metabolites.

L L Christrup1.   

Abstract

Morphine is a potent opioid analgesic widely used for the treatment of acute pain and for long-term treatment of severe pain. Morphine is a member of the morphinan-framed alkaloids, which are present in the poppy plant. The drug is soluble in water, but its solubility in lipids is poor. In man, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) are the major metabolites of morphine. The metabolism of morphine occurs not only in the liver, but may also take place in the brain and the kidneys. The glucuronides are mainly eliminated via bile and urine. Glucuronides as a rule are considered as highly polar metabolites unable to cross the blood-brain barrier. Although morphine glucuronidation has been demonstrated in human brain tissue, the capacity is very low compared to that of the liver, indicating that the M3G and M6G concentrations observed in the cerebrospinal fluid (CSF) after systemic administration reflect hepatic metabolism of morphine and that the morphine glucuronides, despite their high polarity, can penetrate into the brain. Like morphine, M6G has been shown to be relatively more selective for mu-receptors than for delta- and kappa-receptors while M3G does not appear to compete for opioid receptor binding. The analgesic properties of M6G were recognised in the early 1970s and more recent work suggests that M6G might significantly contribute to the opioid analgesia after administration of morphine. The analgesic potency of M6G after intracerebroventricular (ICV) or intrathecal (IT) administration in rats is from 45-800 timer greater than that of morphine, depending on the animal species and the experimental antinociceptive test used. Furthermore, the development of a sensitive high-performance liquid chromatography (HPLC) assay for the quantitative determination of morphine, M6G and M3G has revealed that M6G and M3G were present in abundance after chronic oral morphine administration and that the area under the plasma concentration-time curve exceeded that of morphine. M3G has been found to antagonise morphine and M6G induced analgesia and ventilatory depression in the rat, which has led to the hypothesis that M3G may influence the development of morphine tolerance. M3G exhibits no analgesic effect after ICV or IT administration. Some studies do, however, indicate that M3G may cause non-opioid mediated hyperalgesia/allodynia and convulsions after IT administration in rats. These observations led to the hypothesis that M3G might be responsible for side-effects, hyperalgesia/allodynia and myoclonus seen after high-dose morphine treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9061094     DOI: 10.1111/j.1399-6576.1997.tb04625.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  45 in total

1.  Morphine induced allodynia in a child with brain tumour.

Authors:  S Heger; C Maier; K Otter; U Helwig; M Suttorp
Journal:  BMJ       Date:  1999-09-04

Review 2.  Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairment.

Authors:  Andrew J McLachlan; Sally Bath; Vasi Naganathan; Sarah N Hilmer; David G Le Couteur; Stephen J Gibson; Fiona M Blyth
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

3.  Induction of morphine-6-glucuronide synthesis by heroin self-administration in the rat.

Authors:  Maria Meringolo; Valentina Brusadin; Maria T De Luca; Christian Montanari; Christian L Montanari; Letizia Antonilli; Paolo Nencini; Aldo Badiani
Journal:  Psychopharmacology (Berl)       Date:  2011-10-21       Impact factor: 4.530

Review 4.  Postoperative pain management in children and infants: an update.

Authors:  Christopher Brasher; Benjamin Gafsous; Sophie Dugue; Anne Thiollier; Joelle Kinderf; Yves Nivoche; Robert Grace; Souhayl Dahmani
Journal:  Paediatr Drugs       Date:  2014-04       Impact factor: 3.022

5.  Validation of a HPLC/MS method for simultaneous quantification of clonidine, morphine and its metabolites in human plasma.

Authors:  Fei Tang; Henrietta Bada; Chee M Ng; Markos Leggas
Journal:  Biomed Chromatogr       Date:  2019-03-20       Impact factor: 1.902

6.  Characteristics of distribution of morphine and metabolites in cerebrospinal fluid and plasma with chronic intrathecal morphine infusion in humans.

Authors:  Mark Wallace; Tony L Yaksh
Journal:  Anesth Analg       Date:  2012-07-19       Impact factor: 5.108

7.  The role of mu opioid receptors in psychomotor stimulation and conditioned place preference induced by morphine-6-glucuronide.

Authors:  Alexander T Nguyen; Paul Marquez; Abdul Hamid; Kabirullah Lutfy
Journal:  Eur J Pharmacol       Date:  2012-02-21       Impact factor: 4.432

8.  Morphine metabolite pharmacokinetics during venoarterial extra corporeal membrane oxygenation in neonates.

Authors:  Jeroen W B Peters; Brian J Anderson; Sinno H P Simons; Donald R A Uges; Dick Tibboel
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

9.  Opioids as an alternative to amide-type local anaesthetics for intra-articular application.

Authors:  Irina Ickert; Monika Herten; Melanie Vogl; Christoph Ziskoven; Christoph Zilkens; Rüdiger Krauspe; Jörn Kircher
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2014-05-04       Impact factor: 4.342

10.  Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta.

Authors:  S S Lewis; M R Hutchinson; N Rezvani; L C Loram; Y Zhang; S F Maier; K C Rice; L R Watkins
Journal:  Neuroscience       Date:  2010-01-20       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.